Tobias R. Overbeck
YOU?
Author Swipe
View article: Proteasome inhibition as a potential therapeutic target in thymic cancer
Proteasome inhibition as a potential therapeutic target in thymic cancer Open
Multimodal radio-chemotherapy is the mainstay of treatment for unresectable thymoma (TH) and thymic carcinoma (TC), but there is an urgent need for other therapeutic strategies in these rare tumors. The epithelial cells of the normal thymu…
View article: Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer
Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer Open
Background: A timely systemic therapy of patients with metastasized non-small-cell lung cancer (NSCLC) is a suggestive clinical conception. As the pre-therapeutic management is complex and includes comprehensive immunohistochemical and mol…
View article: Efficacy of targeted therapy in lung cancer with rare ALK fusions
Efficacy of targeted therapy in lung cancer with rare ALK fusions Open
Paradigms about anaplastic lymphoma kinase (ALK)-driven non-small cell lung cancer (NSCLC) have been shaped by EML4::ALK. There is little evidence on the remaining patients, presenting with a plethora of other fusion partners (rare ALK). W…
View article: Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC)
Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC) Open
Higher EDIC is an independent negative prognostic factor in LD-SCLC, correlating with shorter OS, PFS, and DMFS, but had no prognostic relevance in ED-SCLC in this analysis. As immunotherapy becomes part of LD-SCLC treatment, immune-preser…
View article: Delay of systemic therapy confers a survival benefit in patients with stage IV non-small cell lung cancer
Delay of systemic therapy confers a survival benefit in patients with stage IV non-small cell lung cancer Open
Introduction: A timely systemic therapy of patients with metastasized non small cell lung cancer (NSCLC) is a suggestive clinical conception. As the pre-therapeutic management is complex and includes comprehensive immunohistochemical and m…
View article: Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-Targeted therapy in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Thymic Epithelial Tumors
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-Targeted therapy in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Thymic Epithelial Tumors Open
The European Society for Medical Oncology (ESMO) Congress 2024 presented pivotal new data across various trials that continue to explore the nuances of immunotherapy (ICI) in non-small-cell lung cancer (NSCLC) and small cell lung cancer (S…
View article: Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT
Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT Open
View article: Impact of Radiation Dose on Immune Cells (Edic) on Oncologic Outcome in Small Cell Lung Cancer (Sclc)
Impact of Radiation Dose on Immune Cells (Edic) on Oncologic Outcome in Small Cell Lung Cancer (Sclc) Open
View article: Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer Open
View article: Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC Open
View article: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC Open
Background Despite promising outcomes of treatment with anti-programmed cell death (PD)-1/PD-ligand (L)1 agents in combination with platinum-doublet chemotherapy (PDC) in the first-line setting, a significant unmet medical need remains in …
View article: Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy Open
Part of this work has been presented at ESMO annual meeting in Madrid, Spain in October 2023 (Poster 1336 P).
View article: 1334P PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis
1334P PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis Open
View article: Temporal Characterization and Visualization of Revolving Therapy-Events in Lung Cancer Patients
Temporal Characterization and Visualization of Revolving Therapy-Events in Lung Cancer Patients Open
This paper presents a comprehensive workflow for integrating revolving events into the transitive sequential pattern mining (tSPM+) algorithm and Machine Learning for Health Outcomes (MLHO) framework, emphasizing best practices and pitfall…
View article: Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center
Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center Open
In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years. We focused on the impact of chemotherapy regimens, …
View article: Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis Open
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We p…
View article: Outcomes of Multimodal Treatment in Elderly Patients with Localized Non-Small Lung Cancer from a Radiation Oncology Point of View: Special Focus on Low-Dose Cisplatin
Outcomes of Multimodal Treatment in Elderly Patients with Localized Non-Small Lung Cancer from a Radiation Oncology Point of View: Special Focus on Low-Dose Cisplatin Open
Identification of the optimal treatment strategy is challenging in elderly with localized non-small cell lung cancer (NSCLC). Concurrent chemotherapy with low-dose cisplatin represents an option for elderly. Outcomes (1) in elderly (≥70 ye…
View article: And Yet It Moves: Clinical Outcomes and Motion Management in Stereotactic Body Radiation Therapy (SBRT) of Centrally Located Non-Small Cell Lung Cancer (NSCLC): Shedding Light on the Internal Organ at Risk Volume (IRV) Concept
And Yet It Moves: Clinical Outcomes and Motion Management in Stereotactic Body Radiation Therapy (SBRT) of Centrally Located Non-Small Cell Lung Cancer (NSCLC): Shedding Light on the Internal Organ at Risk Volume (IRV) Concept Open
The internal organ at risk volume (IRV) concept might improve toxicity profiles in stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). We studied (1) clinical aspects in central vs. peripheral tumors, (2) the…
View article: Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer Open
Entrectinib has continued to demonstrate deep and durable systemic and IC responses in patients with NTRK-fp NSCLC.
View article: Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer Open
G12C/TP53 comutations identify a subset of patients with a very favorable long-term survival with immune checkpoint inhibitor monotherapy, mediated by highly active interferon gamma signaling in a proinflammatory TME.
View article: 1300P Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
1300P Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab Open
Background: The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy after first-line durvalumab plus chemotherapy in extensivestage small cell lung cancer (ES-SCLC).Methods: A total of 122 patients with…
View article: 1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data
1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data Open
View article: 1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial
1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial Open
View article: 1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy Open
View article: Predictors of lower exercise capacity in patients with cancer
Predictors of lower exercise capacity in patients with cancer Open
Maintaining cancer patients’ exercise capacity and therefore patients’ ability to live a self-determined life is of huge importance, but little is known about major determinants. We sought to identify determinants of exercise capacity in p…
View article: Social participation during the COVID-19 pandemic in persons with a high risk for a severe course of COVID-19 – results of a longitudinal, multi-center observational study in Germany
Social participation during the COVID-19 pandemic in persons with a high risk for a severe course of COVID-19 – results of a longitudinal, multi-center observational study in Germany Open
Social participation improved in persons with a high risk for a severe COVID-19 course during the pandemic. The local COVID-19 incidence showed a negative association with social participation only until the fall of 2021 when it was used a…
View article: NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients
NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients Open
(1) Background: The main objectives of our study are (i) to determine the prevalence of NTRK (neurotrophic tyrosine kinase) fusions in a routine diagnostic setting in NSCLC (non-small cell lung cancer) and (ii) to investigate the feasibili…
View article: Optimizing the structure of interdisciplinary tumor boards for effective cancer care
Optimizing the structure of interdisciplinary tumor boards for effective cancer care Open
Introduction Multi-professional interdisciplinary tumor boards (ITB) are essential institutions to discuss all newly diagnosed, relapsed or complex cancer patients in a team of specialists to find an optimal cancer care plan for each indiv…
View article: Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors
Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors Open
Background The advent of immune checkpoint inhibitors (ICIs) has powerfully broadened the scope of treatment options for malignancies with an ongoing increase of indications, but immune-related adverse events (irAEs) represent a serious th…
View article: Management of Aortoesophageal Fistula in a Palliative Patient with Non-Small-Cell Lung Cancer: A Case Report
Management of Aortoesophageal Fistula in a Palliative Patient with Non-Small-Cell Lung Cancer: A Case Report Open
Introduction: Aortoesophageal fistulas are a rare but life-threatening complication in patients with thoracic malignancies. Case Presentation: We describe a case of a 55-year-old female patient with metastatic non-small-cell lung cancer. D…